Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus Disease | Zendy

Arthur Viodé | Zendy; Kinga K. Smolen | Zendy; Benoit Fatou | Zendy; Zainab Wurie | Zendy; Patrick van Zalm | Zendy; Mandy Kader Kondé | Zendy; Balla Moussa Kéita | Zendy; Richard Amento Ablam | Zendy; Eleanor N. Fish | Zendy; Hanno Steen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus Disease

Author(s) -

Arthur Viodé,

Kinga K. Smolen,

Benoit Fatou,

Zainab Wurie,

Patrick van Zalm,

Mandy Kader Kondé,

Balla Moussa Kéita,

Richard Amento Ablam,

Eleanor N. Fish,

Hanno Steen

Publication year - 2022

Publication title -

mbio

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.562

H-Index - 121

eISSN - 2161-2129

pISSN - 2150-7511

DOI - 10.1128/mbio.00567-22

Subject(s) - ebola virus , proteome , outbreak , disease , virology , proteomics , ebolavirus , chemokine , virus , medicine , biology , computational biology , immunology , bioinformatics , inflammation , gene , genetics

As evidenced by the 2013–2016 outbreak in West Africa, Ebola virus (EBV) disease (EVD) poses a major global health threat. In this study, we characterized the plasma proteomes of 12 individuals infected with EBV, using two different LC-MS-based proteomics platforms and an antibody-based multiplexed cytokine/chemokine assay.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research